conferences  2015

We are in the process of arranging our forthcoming events and conference schedule for the rest of 2015.

Our scientists will be present at the following events and we’d be happy to meet to discuss our outsourcing offering:

Event: ELRIG Drug Discovery 2015
Date: 2-3 September 2015
Venue: Telford, UK

Event: 18th SCI/RSC Medicinal Chemistry Symposium: Drugging the Undruggable
Date: 13-16 September 2015
Venue: Churchill College, Cambridge, UK

Event: FMC 2015 Frontiers in Medicinal Chemistry
Date: 14-16 September 2015
Venue: Antwerp, Belgium

Event: The Expanding Toolbox of Medicinal Chemistry: From Chemical Biology to Clinical Applications
Date: 16 October 2015
Venue: Dijon, France

Should you wish to arrange a meeting in advance at any of these events, please contact:

Robin Wilkes

Charnwood Molecular Joint Venture

Charnwood Molecular’s recent partnership to launch a new service identifying interactions between small molecules and protein targets has received recognition within the European Eurostars programme that part funded its development.

Working with French company, Hybrigenics, Charnwood used its expertise to link molecules for further analysis by the Paris-based company, using their yeast molecular biology machinery.

The venture is the result of a two year long commercial trialling phase, which was supported by European funding under the Eurostars programme.

ULTImate YChemH is a chemical biology tool for direct targets identification. This method is based on the well-established yeast two-hybrid (Y2H) technology.

More details are available on the Eurostars website here:

Conferences 2015

We have now finalised our forthcoming events and conference schedule for the next part of 2015. This list may be added to, but so far we have confirmed attendance at the following International events.

Our representatives will be in attendance and we’d be happy to meet there to discuss any aspect of your business that you feel Charnwood Molecular can assist with:

Event: World Preclinical Congress: Mastering Med Chem & Property-Based Drug Design
Date: 10-12 June 2015
Venue: Boston, MA, USA

Event: RICT 2015 Drug Discovery and Selection: Understanding Targets and Mechanisms
Date: 1-3 July 2015
Venue: Avignon, France

Event: Spanish-Italian Med Chem Congress (SIMCC-2015)
Date: 12-15 July 2015
Venue: Barcelona, Spain

Event: 18th SCI/RSC Medicinal Chemistry Symposium: Drugging the undruggable
Date: 13-16 September 2015
Venue: Churchill College, Cambridge, UK

Should you wish to arrange a meeting in advance at any of these events, please contact:

Robin Wilkes


As part of the ongoing growth and development of its business, Charnwood Molecular has secured the services of Dr. David Lathbury.

Dr Lathbury has over 25 years of industrial experience in the fine chemical, agrochemical, and pharmaceutical fields. Over the last 20 years he has worked in the pharmaceutical arena at SmithKline Beecham, and at AstraZeneca, where he was Head of Process Chemistry. Most recently he was Vice President of Chemical Development at Albany Molecular Research in Syracuse, New York.

During his extensive career, David has worked on four marketed drugs, including process re-development activities on “Seroquel” and “Paxil”. During his time at AstraZeneca, his team was responsible for the chemical development of “Iressa” and “Crestor”. He is author or co-author on 30 publications and patents.

David is a Fellow of the Royal Society of Chemistry and is a visiting Professor at Bristol University. He is also a member of the EPSRC strategic advisory team and was Chair of the 2012 Gordon Research Conference on Heterocyclic Compounds.

David will now work with a team of experienced scientists at Charnwood Molecular to build a unique and sector-leading Chemical and Process Development service to add to Charnwood’s existing Contract Research activities in Medicinal Chemistry, Custom Synthesis and Contract Research.

For more information, please contact Dr. Robin Wilkes, Director of Business Development (Medicinal Chemistry) at

Proteinase 2015

Charnwood Molecular is exhibiting at the forthcoming Proteinaise 2015 – 9th RSC / SCI symposium on Proteinase Inhibitor Design.

The event takes place from the 13th to 14th April, at Novartis, Basel, Switzerland.

This symposium will cover progress in the design and synthesis of protease inhibitors for a diverse range of disease indications, while also covering a range of novel drug discovery activities: from ‘Molecules to Medicines’. The event is aimed at medicinal chemists and other scientists interested in furthering their knowledge of proteases in the context of drug discovery.

Charnwood will be exhibiting at the event and explaining its expertise in drug discovery activities and process development.

If you are in attendance at the event and would like to meet, please email:


Charnwood Molecular will be taking part in a forthcoming trade mission to Denmark, alongside its strategic partners.

The mission will be heading to Denmark on the 25th March 2015 on a market visit supported by UKTI and hosted at the residence of the British Ambassador in Copenhagen.

The market visit, entitled: “The Changing Face of Pharmaceutical Discovery and Development – A Collaborative CRO Approach” will provide an opportunity for life science research companies across the Nordik region to meet and discuss how collaborative outsourcing can overcome the key scientific challenges within R&D.

Charnwood Molecular has been keen in developing the approach and has seized the opportunity to promote the collaborative approach to win new business.

Aimed at R&D scientists, project leaders and resource managers, the meeting will consist of opening presentations reflecting on current trends in outsourcing worldwide with particular reference to Scandinavia.

Representatives from all CROs will give an overview of how their services are applied to problem solving within the R&D pipeline. Further discussion is then planned to explore opportunities.

“We aim to capitalise on the collaborative approach that this trip gives and places us ideally to help Nordik companies looking for support with their research projects,” states Dr Robin Wilkes, Business Development Director – Medicinal Chemistry at Charnwood Molecular. “We are keen to work together with these companies that naturally complement our services and this is another vehicle to do so.”

The companies attending complement Charnwood Molecular in their drug discovery activities and process development. Aurelia BioScience covers compound screening to identify hit and lead molecules. XenoGesis are specialists in drug metabolism and pharmacokinetics (DMPK) testing. Reach Separations provides the analytical and chromatographic expertise, particularly for chiral compounds. Molecular Profiles provides pharmaceutical development services and clinical trial manufacturing for small molecules and can work from early phase development to late stage clinical manufacture. Biopta addresses the issue of translational relevance, proving data from tailored fresh human tissue assay systems; interfacing with the other groups by testing novel molecules for efficacy, absorption or safety in healthy and diseased tissue.

The market visit follows a successful two-day visit to Switzerland last year organised and supported by UKTI.

New Equipment 2015

Charnwood Molecular has again increased its capabilities with the acquisition of two new pieces of equipment – a new photochemical reactor and a new ozone generator.

Rayonet RMR-200 Photochemical Reactor:
Allowing reaction volumes up to 2L, the Rayonet reactor is a state of the art device, needing no eternal cooling. It is an intense, safe source of ultraviolet light at 254nm using 16 separate light sources.

Designed for the photolysis of hetercyclic compounds, ketones, halogen derivatives, olefins etc, the reactor opens up a whole new area of chemistry that Charnwood Molecular can offer its clients.

Triogen LAB2B Ozone generator:
The LAB2B ozone generator is a small air-cooled unit designed for bench use incorporating function indicators, feed gas flowmeter and variable output control. Operating on various feed gases such as dried air or oxygen the LAB2B is capable of producing concentrations up to 10% volume.

conferences  2015

We are in the process of arranging our forthcoming events and conference schedule for the coming year.

Our scientists intend to be present at the following one day events in the first half of 2015 and we’d be happy to meet there to discuss our outsourcing offering:

Event: RSC Nucleosides and Nucleotides symposium: synthetic and biological chemistry
Date: 17 April 2015
Venue: RSC, London

Event: Drug Discovery Chemistry
Date: 21-23 April 2015
Venue: San Diego, CA, USA

Event: 26th Symposium on Medicinal Chemistry in Eastern England
Date: 23 April 2015
Venue: Hatfield, Hertfordshire

Event: WPC – World Preclinical Congress
Date: 10-12 June 2015
Venue: Boston, MA, USA

Should you wish to arrange a meeting in advance at any of these events, please contact:

Robin Wilkes

blog newstory

We have recently launched a new blog on our site, which airs the views of one of our chemists, Phil Thorne MRSC C.Chem. Phil is a Senior Research Chemist at Charnwood and the blog gives him the opportunity to share issues of the day with like-minded or interested readers.

The blog will be updated regularly with pertinent stories on both drug discovery issues and the wider scientific environment. We hope you find both an interesting and informative read.

The blog can be read here:

mtsc oxford university
We have added a further event to our forthcoming conference schedule for the month of December.

We will now also be in attendance at the following event:

Event: The Future of Drug Discovery: Open Innovation
Date: 4 December, 2014
Venue: Medical Sciences Teaching Centre, University of Oxford

Should you wish to meet our representative at this event, please email: